Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ikena Oncology Inc (NQ: IKNA )

5.970 -0.220 (-3.55%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 35,848
Open 6.120
Bid (Size) 5.970 (1)
Ask (Size) 9.550 (2)
Prev. Close 6.190
Today's Range 5.810 - 6.120
52wk Range 1.940 - 7.640
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Ikena Oncology to Participate in Upcoming Investor Conferences
From Ikena Oncology, Inc.
Via GlobeNewswire
Analyst Ratings for Ikena Oncology
 
Via Benzinga

Performance

YTD
+127.86%
+127.86%
1 Month
+8.94%
+8.94%
3 Month
+47.04%
+47.04%
6 Month
+146.69%
+146.69%
1 Year
+53.08%
+53.08%

More News

Read More
Ikena Oncology Reports First Quarter 2023 Financial Results and Highlights Advancements Across Targeted Oncology Pipeline
From Ikena Oncology, Inc.
Via GlobeNewswire
Ikena Oncology Announces $40 Million Underwritten Offering
From Ikena Oncology, Inc.
Via GlobeNewswire
Credit Suisse Maintains Outperform Rating for Ikena Oncology: Here's What You Need To Know
Via Benzinga
Ikena Oncology Earnings Perspective: Return On Capital Employed
Via Benzinga
Ikena Oncology's Return On Capital Employed Insights
Via Benzinga
Ikena Oncology to Participate in the Stifel 2023 Virtual Targeted Oncology Days
From Ikena Oncology, Inc.
Via GlobeNewswire
Ikena Oncology Shares Differentiation Profile of IK-930, a Novel Hippo-Pathway Inhibitor, Including Projected Therapeutic Index Advantages and Breadth of Patient Populations at AACR 2023 Annual Meeting
From Ikena Oncology, Inc.
Via GlobeNewswire
Ikena Oncology Reports Fourth Quarter and Full Year 2022 Financial Results
From Ikena Oncology, Inc.
Via GlobeNewswire
Ikena Oncology Presents Preclinical Data on IK-595, Best-in-Class Next-Generation MEK-RAF Complex Inhibitor, in Plenary Session at AACR Special Conference on RAS Targeting
From Ikena Oncology, Inc.
Via GlobeNewswire
Ikena Oncology: Q3 Earnings Insights
Via Benzinga
Ikena Oncology Receives FDA Fast Track Designation for Novel AHR Antagonist IK-175 in Combination with Nivolumab to Treat Urothelial Carcinoma
From Ikena Oncology, Inc.
Via GlobeNewswire
Ikena Oncology to Participate in Cowen 43rd Annual Health Care Conference
From Ikena Oncology, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Ikena Oncology Appoints Owen Hughes as Board Chair
From Ikena Oncology, Inc.
Via GlobeNewswire
Why Ambrx Biopharma Shares Are Trading Higher By Over 550%? Here Are 52 Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Ikena Oncology Announces New Cancer Program, Shelves Early Asset For Colorectal Cancer
Via Benzinga
Ikena Oncology Announces New Program in Next-Generation MEK-RAF Inhibition and Provides Corporate Update
From Ikena Oncology, Inc.
Via GlobeNewswire
Ikena Oncology to Participate in the Piper Sandler 34th Annual Healthcare Conference
From Ikena Oncology, Inc.
Via GlobeNewswire
Ikena Oncology Announces Initial Clinical Data from IK-175 Program in Urothelial Carcinoma
From Ikena Oncology, Inc.
Via GlobeNewswire
UPDATE -- Ikena Oncology Reports Third Quarter 2022 Financial Results and Provides a Corporate Update
From Ikena Oncology, Inc.
Via GlobeNewswire
Ikena Oncology Reports Third Quarter 2022 Financial Results and Provides a Corporate Update
From Ikena Oncology, Inc.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Monday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.